Alexander Kutikov, MD, FACS

​​
This physician is not currently rated. Why?

Why is this doctor not rated?

Close

To ensure the accuracy of our patient satisfaction scores, we require that providers who see patients receive a minimum number of completed patient-submitted surveys before their reviews are listed on their profiles. Star ratings on this site are collected on a rolling basis from the previous 12 months.
Additionally, some of the physicians listed on our site do not see patients directly, and therefore, do not receive evaluation and ratings from patients.

More about patient ratings

Dr. Kutikov is a member of the Philadelphia Inquirer's Health Advisory Panel.

You can find some of his selected Inquirer pieces here.

Request an Appointment

Clinical Locations

Chair, Department of Urology

Professor, Department of Urology

Roberta R. Scheller Chair in Urologic Oncology

 

Treatment Focus

Minimally Invasive Surgery, Robotic Surgery, Laparoscopic Surgery, Traditional Open Surgery
Prostate Cancer: robotic and open radical nerve-sparing prostatectomy
Bladder Cancer: urinary diversion, orthotopic neobladder reconstruction
Kidney Cancer: kidney-sparing approaches, robotic, laparoscopic, open kidney surgery.
Adrenal masses: minimally-invasive adrenal surgery and extensive expertise in treatment of adrenal incidentalomas.

Research Program

Language(s) Other than English

  • Russian

Treatment Philosophy

I am a surgical specialist who treats tumors of the adrenal, kidney, prostate, bladder, testis, and other genitourinary organs. Working closely with other members of the Fox Chase multidisciplinary team, I make certain that my patients are aware of all the choices that today's cutting edge oncological care has to offer, regardless of whether these treatments take place inside or outside the operating room.

When surgery is necessary, I strive to offer the best operation that fits an individual's particular condition and circumstance. Indeed, my unique fellowship training in both traditional open surgery and minimally-invasive approaches such as laparoscopy and robotics, allows me to offer a wide range of options that optimize oncological outcomes and minimize recovery time. For example, I am skilled at both open and robot-assisted nerve-sparing prostatectomy and open, laparoscopic, and robotic kidney surgery. Particularly, I have advanced expertise in kidney preservation. For patients with bladder cancer, I am able to offer both bladder-sparing approaches and the latest techniques in continent urinary reconstruction. Furthermore, I have a particular interest and expertise in treatment of various tumors and conditions that stem from the adrenal gland.

As a clinician at an academic institution such as Fox Chase, I actively participate in medical research. In particular, my academic interests focus on kidney, prostate, bladder, and adrenal disease. Being an active contributor to the medical literature, I hope to offer my patients the most up-to-date information on medical progress and, if necessary, help them enroll into appropriate clinical trials — many of which are only available through Fox Chase.

Modern oncology offers patients tremendous hope; however, today's treatment options can be overwhelming, especially to those who are trying to cope with the shock of a recent cancer diagnosis. I greatly appreciate the toll that such a diagnosis can take not only on the patient, but also on his or her family. I hope to bring to every one of my patients a sense of understanding and compassion that can help us effectively work together to achieve the best outcome that modern medicine has to offer.

Lab Overview

In collaboration with Vladimir Kolenko, MD, PhD, and Robert Uzzo, MD, our research efforts span the basic and the clinical sciences. Our work focuses on understanding the process of renal and prostatic carcinogenesis and assessing novel therapeutic regimens for the treatment of urological cancers.

As part of our work, we explore the role of zinc in development and progression of prostate malignancy.  Zinc concentrations diminish early in the course of prostate carcinogenesis—prior to histopathological changes—and continue to decline during progression toward castration-resistant growth. The objective of research in our laboratory is to test and advance an emerging paradigm that intracellular zinc deficiency augments malignant potential of prostate cancer cells and, therefore, promotes prostate tumorigenesis. We are also investigating the role of zinc chelators as potential therapeutic agents for the treatment of castration-resistant prostate cancer. Work performed by Dr. Kolenko indicates that treatment of prostate cancer cells with the zinc chelating agent TPEN induces selective down-regulation of X-linked inhibitor of apoptosis protein (XIAP) and sensitizes cancer cells to cytotoxic agents. Importantly, the observed effect is not limited to prostate cancer, as TPEN reduces expression of XIAP in malignant cell lines of various origins, e.g. colon, ovarian, leukemia, breast and cervical.

The second major theme of our research is to determine the mechanism of tyrosine kinase inhibitor (TKIs)-resistance in genitourinary tumors. Our studies reveal that TKI-resistance coincides with the loss of phosphatase and tensin homolog (PTEN) protein expression in prostate and renal malignant cells. On the contrary, expression of PTEN sensitizes prostate and renal tumors to multi-targeted tyrosine kinase inhibitor sunitinib both in vitro and in vivo. In addition, our studies indicate that an increase in expression of IL-6 and IL-8 correlates with sunitinib and pazopanib resistance in prostate and renal tumor cells. Use of a reliable biomarker for TKI response, harbors promise both in the clinical and research settings.

In the clinical arena, we focus our efforts on addressing quantification of competing risks of death for patients with urologic malignancies, investigating the biology and natural history of small renal masses, improving reporting and risk-stratification of surgical outcomes for patients with kidney cancer, and addressing clinical approaches to patients with adrenal cancers and incidental adrenal masses.

Educational Background

  • Fellow, Society of Urologic Oncology, Fox Chase Cancer Center, Philadelphia, PA
  • Chief Resident, Urology, University of Pennsylvania, Philadelphia, PA, 2007-2008
  • Resident, Urology, University of Pennsylvania, Philadelphia, PA, 2004-2007
  • MD, Harvard Medical School, Harvard-MIT Health Sciences and Technology Program, Boston, MA, 2003

Certifications

  • American Board of Urology, Board Certified

Memberships

  • Society of Urologic Oncology
  • American Urological Association
  • American College of Surgeons
  • Philadelphia Urological Society

Honors & Awards

  • Young Urologist of the Year, Mid-Atlantic Section, American Urological Association, 2021
  • Philadelphia Magazine Top Doctors, 2017-21
  • Best Doctors in America® , 2019-2020, Urology
  • Everyday Hero Award, Pennsylvania Medical Society (PAMED), 2018
  • America's Top Doctors®2016-17
  • BJU International Journal Best Mobile App Award for drawMD Urology iPad Application, American Urological Association Meeting, San Diego, CA, 2013
  • Mid-Atlantic AUA Young Investigator Representative to the AUA’s Research Forum, American Urological Association Meeting, Washington, DC, 2011
  • CaPSURE Scholar, CaPSURE Scholars Program in Prostate Cancer Outcomes Research, 2009-10
  • American College of Surgeons Excellence in Research Award 96th Annual Clinical Congress, Surgical Forum, 2010

William Bojanowski

  • Neuroendocrine Tumors

In October of 2020, at 59 years old, I started having some back pain. I worked in construction, so lower back pain was normal, but this time the pain was in my upper back. I went to my primary doctor and she noticed that my kidney was not functioning fully. She thought it might be due to my diabetes medication.

After two months of a lowered dosage of medication, my pain only got worse. I was sent to the local urologist, and when he saw something on my X-rays he immediately referred me to Fox Chase Cancer Center.

VIEW PATIENT STORY

Edward Enoch

  • Prostate Cancer

My name is Edward Enoch, and I am from Lansdale, Pennsylvania. I was sixty years old and two years retired when my life took a startling turn.

Like millions of other retirees, my wife Janice and I were updating our health insurance. We met with an agent who asked that I schedule a routine checkup. I thought nothing of it at the time—after all, I had no complaints about my health. However, once I received the results of my blood test, the confidence I had regarding my health started to waver.

VIEW PATIENT STORY

Charles "Cha" Goods

  • Prostate Cancer

I’ve been a tennis coach for nearly 17 years, the last dozen at Legacy Youth Tennis and Education in Philadelphia. I run group clinics and offer private lessons. I specialize in movement and footwork training, as well as video-based training. My students range from kids as young as five to professional tennis players. I’m an active coach. When I teach my students how to do something, I want to show them I can do it. They’re amazed at how good I am!

VIEW PATIENT STORY

Research Interests

Dr. Kutikov has authored over 300 peer-reviewed publications.  His current research interests include understanding carcinogenesis of genitourinary cancers, risk-stratification of surgical outcomes, and quantification of competing risks.  He serves on editorial boards of academic journals, including being the Associate Editor of Digital Media for European Urology, the field of Urology's leading academic publication.

Dr. Kutikov also has significant interests in harnessing web and mobile technology to improve patient engagement and quality of care.  He is a co-founder of several ventures that strive to improve physician education and patient care.  

Selected Publications

Bernstein A.N., Nourian A., Strother M., Lobo A., Devarajan K., Richman D., Hill M.V., Conrad L., Magagna A., Viterbo R., Greenberg R., Chen D., Smaldone M., Correa A., Uzzo R., Kutikov A., Harnessing choice architecture in urologic practice: Implementation of an opioid-sparing protocol grounded in cognitive behavioral theory. Urol Oncol. 40(3): 95-102, 2022. https://www.ncbi.nlm.nih.gov/pubmed/34876350.

Klaassen Z., Vertosick E., Vickers A.J., Assel M.J., Novara G., Pierce C., Wallis C.J.D., Larcher A., Cooperberg M.R., Catto J.W.F.,Kutikov A., Optimal dissemination of scientific manuscripts via social media: A prospective trial comparing visual abstracts versus key figures in consecutive original manuscripts published in European Urology. Eur Urol, 2022. https://www.ncbi.nlm.nih.gov/pubmed/35151514.

Strother M.C., Cho E.Y., Loecher M., Strauss D., Chandra A., Handorf E., Yu J., Chen D.Y.T., Uzzo R., Levin L., Anaokar J., Kutikov A., The delayed nephrogram: Point-of-care quantitative measurement, validation as an indicator of obstruction, and novel use as a predictor of renal functional impairment. Eur Urol Focus, 2022. https://www.ncbi.nlm.nih.gov/pubmed/35181283.

Chandrasekar T., Boorjian S.A., Capitanio U., Gershman B., Mir M.C.,Kutikov A., Collaborative review: Factors influencing treatment decisions for patients with a localized solid renal mass. Eur Urol. 80(5): 575-588, 2021. https://www.ncbi.nlm.nih.gov/pubmed/33558091.

A. G. McIntosh, D. C. Parker, B. L. Egleston, R. G. Uzzo, H. Haseebuddin, S. S. Joshi, R. Viterbo, R. E. Greenberg, D. Y. T. Chen, M. C. Smaldone, and Kutikov, “Prediction of Significant Estimated Glomerular Filtration Rate Decline Following Renal Unit Removal to Aid in the Clinical Choice between Radical and Partial Nephrectomy in Patients with Renal Mass and Normal Renal Function,” BJU Int, May 2019. PubMed

H. Borgmann, M. Cooperberg, D. Murphy, S. Loeb, J. N’Dow, M. J. Ribal, H. Woo, M. Rouprêt, A. Winterbottom, C. Wijburg, M. Wirth, J. Catto, and A. Kutikov, “Online Professionalism—2018 Update of European Association of Urology (@Uroweb) Recommendations on the Appropriate Use of Social Media,” European Urology, pp. 1–7, Aug. 2018. PubMed

M. C. Smaldone, B. Egleston, J. M. Hollingsworth, B. K. Hollenbeck, D. C. Miller, T. M. Morgan, S. P. Kim, A. Malhotra, E. Handorf, Y.-N. Wong, R. G. Uzzo, and A. Kutikov, “Understanding Treatment Disconnect and Mortality Trends in Renal Cell Carcinoma Using Tumor Registry Data,” Med Care, vol. 55, no. 4, pp. 398–404, Apr. 2017. PubMed

N. Waingankar, K. Mallin, M. Smaldone, B. L. Egleston, A. Higgins, D. P. Winchester, R. G. Uzzo, and A. Kutikov, “Assessing the relative influence of hospital and surgeon volume on short-term mortality after radical cystectomy,” BJU Int, vol. 120, no. 2, pp. 239–245, Aug. 2017. PubMed

B. T. Ristau, D. Y. T. Chen, J. Ellis, A. Malhotra, L. DeMora, R. B. Parsons, B. Milestone, M. Brody, R. Viterbo, R. Greenberg, M. Smaldone, R. Uzzo, J. Anaokar, and A. Kutikov, “Defining Novel and Practical Metrics to Assess the Deliverables of Multiparametric Magnetic Resonance Imaging/Ultrasound Fusion Prostate Biopsy,” The Journal of Urology, Oct. 2017. PubMed

S. P. Kim, S. C. Campbell, I. Gill, B. R. Lane, H. Van Poppel, M. C. Smaldone, A. Volpe, and A. Kutikov, “Collaborative Review of Risk Benefit Trade-offs Between Partial and Radical Nephrectomy in the Management of Anatomically Complex Renal Masses,” European Urology, vol. 72, no. 1, pp. 64–75, Jul. 2017. PubMed... Expand

Additional Publications

The following ratings and reviews are based on verified feedback collected from independently administered patient experience surveys. The ratings and comments submitted by patients reflect their own views and opinions. Patient identities are withheld to ensure confidentiality and privacy. Learn more about our Patient Experience Ratings.

Ratings Breakdown

Loading ...

Patient comments

Loading ...
​​

Dr. Kutikov is a member of the Philadelphia Inquirer's Health Advisory Panel.

You can find some of his selected Inquirer pieces here.